GlassScriptPhysician profile
Chad M Klug
NPI 1780835215
$8,333.24
in general payments reported to CMS, 2019-2025
34 companies · $2,305 in 2025
The $2,305 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,743 · 2022: $1,537 · 2023: $1,079 · 2024: $1,669 · 2025: $2,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,892 · Travel and Lodging: $855 · Consulting Fee: $200 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,892.45 |
| Travel and Lodging | $854.55 |
| Consulting Fee | $200.00 |
| Education | $106.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,426.77 | 2025 | |
| Amgen INC. | $788.79 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $701.82 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $482.17 | 2021-2025 | |
| Medtronic, INC. | $474.34 | 2021-2025 | Symplicity G3, Linq II |
| Janssen Pharmaceuticals, INC | $470.03 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $448.61 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $395.58 | 2021-2025 | Verquvo, Winrevair |
| Pfizer INC. | $357.79 | 2021-2025 | |
| Esperion Therapeutics, INC. | $350.10 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $343.31 | 2021-2024 | Farxiga |
| Kestra Medical Technology Services, INC. | $279.34 | 2022-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $195.14 | 2021-2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $179.55 | 2021-2023 | |
| Cvrx, INC. | $154.25 | 2022-2025 | Barostim Neo System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.71 | 2022-2023 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $149.16 | 2021-2024 | Evkeeza |
| Janssen Scientific Affairs, LLC | $146.00 | 2023 | Xarelto |
| Amarin Pharma, INC. | $129.57 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $122.55 | 2024 | Uptravi, Opsumit |
| Novo Nordisk INC | $104.24 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Vifor Pharma, INC. | $69.93 | 2021-2022 | |
| Abbott Laboratories | $53.66 | 2024-2025 | Aveir, Cardiomems |
| Chiesi USA, INC. | $50.08 | 2021-2024 | Kengreal, Cleviprex |
| Daiichi Sankyo INC. | $48.85 | 2024 | Injectafer |
| Astellas Pharma US INC | $46.85 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $44.95 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $35.42 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $30.54 | 2021 | |
| United Therapeutics Corporation | $27.10 | 2025 | Tyvaso |
| Btg International INC. | $24.00 | 2024 | |
| Lilly USA, LLC | $18.93 | 2023 | Mounjaro |
| Kiniksa Pharmaceuticals International, Plc | $16.01 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $14.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Klug listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.